Navigation Links
Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Date:6/18/2012

LAUSANNE, Switzerland and SUZHOU, China, June 18, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc. (Ascepion), a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialisation of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development. ASP-08126 is a potent orally available small molecule that binds and inhibits several tyrosine kinase oncogenes implicated in many aspects of cancer development including tumour growth, metastasis, and tumour angiogenesis. ASP-08126 is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.

"The potential of Debio 1144 to simultaneously inhibit many aspects of cancer development is making that substance extremely attractive to Debiopharm", said Rolland-Yves Mauvernay, President and founder of Debiopharm, who added "Debio 1144 has the potential of helping patients suffering from several tumour types. Due to its inhibition profile Debio 1144, is expected to lead to high anti-tumour efficacy."

"We are very pleased to collaborate with Debiopharm, a company with track records and expertise in the development of cancer medicines, to develop our innovative cancer therapeutics. The formation of this partnership will facilitate the development of ASP-08126 and benefit cancer patients ultimately", stated Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.

About Debiopharm Group

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with
'/>"/>

SOURCE The Debiopharm Group and Ascepion Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
4. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA ... financial results for the second quarter and three and six ... expressed in Canadian dollars and in accordance with International Financial ... ESSA recorded a net loss of $5.9 million ($0.35 ... 2015 (Q2-2015), compared to a net loss of $0.4 million ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2
... Associates, of New Jersey awarded General Program Prize Paper at ... ... 18 Researchers at,Reproductive Medicine Associates of New Jersey (RMA) ... Reproductive Medicine (ASRM),for developing a novel technology making it possible ...
... Corporation,announced today that enrollment has completed in a ... to enhance memory. The,IMPACT ("Improvement in Memory with ... than five hundred adults aged 65+,seeking to improve ... Principal Investigators for the IMPACT trial are Elizabeth ...
Cached Medicine Technology:Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 2Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 3Study Demonstrates Mindful Approach to Aging 2Study Demonstrates Mindful Approach to Aging 3
(Date:5/29/2015)... 29, 2015 What does community do? ... Foundation, community comes together to plant gardens, to teach ... and awareness of critical issues. Community invites everyone to ... beyond. , "What Community Does" was commissioned by The ... Colorado, and released during the foundation’s Annual Celebration in ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... CO (PRWEB) May 29, 2015 ... new addiction, substance abuse, and co-occurring mental health ... and ribbon cutting for the general public on ... 2nd. , The Recovery Village at Palmer Lake ... intensive outpatient programming, utilizing traditional and evidence-based therapies, ...
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at ... great fun!”, she exclaimed. “I’ve always wanted to jump from ... thought this would be ok.” , “We put on nylon coveralls, ... described. “I don’t remember it being noisy, but the wind ...
Breaking Medicine News(10 mins):Health News:What Community Does: A New Video from The Denver Foundation 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Indoor Skydiving Brings Thrills to Seniors 2
... LOUISVILLE, Ky., Dec. 5 Ventas, Inc. ... that the Executive,Compensation Committee of its Board ... to certain executive officers to encourage their,long-term ... granted to,Raymond J. Lewis, the Company,s Chief ...
... -- Apart from a more complicated medical case, ... time with their patients" Researchers at UC Davis ... that affect the length of a patients medical ... the doctors visit. , In a new ...
... gene involved in communication among brain cells has a direct ... study by scientists supported by the National Institute on Alcohol ... Health (NIH), and the U.S. Army. , Scientists do not ... effect on alcohol consumption, exists in humans. , Known ...
... Ltd., (Amex: CPD ) announced today that ... final approval for the Company,s,Abbreviated New Drug Application ... and 10 mg (Amlodipine)., Amlodipine is indicated ... of chronic stable angina, and for the treatment ...
... Software Healthcare, Inc.,announced today that more than 500 ... Management system during the 2007 fiscal year,with the ... EHR by,Sage Electronic Health Records system., "Electronic ... our,customer base as well as new customers. These ...
... with those already carrying the virus , WEDNESDAY, Dec. 5 ... virus that causes AIDS) choose to have unprotected sex only ... from six clinics in San Francisco, New York City, Los ... study included 27 men with acute HIV infection. This refers ...
Cached Medicine News:Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2Health News:Scientists identify gene that influences alcohol consumption 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R) 2Health News:Sage Software Healthcare, Inc. Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 2Health News:Newly HIV-Infected Gay Men Select Other Infected Partners 2
The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
The SportStat Pulse Oximeter shines red and infrared light through a finger and detects the fluctuating signals caused by blood flow. Pulse rate is determined from the signals received by a light det...
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
The FetalSAT™ System with DualSens Sensor displays continuous, real-time fetal pulse oximetry (FSpO2) and fetal pulse rate (FPR) values in one compact monitor....
Medicine Products: